Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361949063> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4361949063 abstract "<div>Abstract<p><b>Purpose:</b> Transforming growth factor-β (TGF-β) is an immunosuppressive cytokine, having direct suppressive activity against conventional CD4<sup>+</sup> and CD8<sup>+</sup>T cells and natural killer cells, thereby inhibiting tumor immunosurveillance. Here, we investigated possible synergy between anti–TGF-β (1D11) and a peptide vaccine on induction of antitumor immunity, and the mechanisms accounting for synergistic efficacy.</p><p><b>Experimental Design:</b> The effect of combination treatment with a peptide vaccine and anti–TGF-β was examined in a subcutaneous TC1 tumor model, as well as the mechanisms of protection induced by this treatment.</p><p><b>Results:</b> Anti–TGF-β significantly and synergistically improved vaccine efficacy as measured by reduction in primary tumor growth, although anti–TGF-β alone had no impact. The number of tumor antigen–specific CTL with high functional avidity as measured by IFN-γ production and lytic activity was significantly increased in vaccinated mice by TGF-β neutralization. Although TGF-β is known to play a critical role in CD4<sup>+</sup>Foxp3<sup>+</sup> Treg cells, Treg depletion/suppression by an anti-CD25 monoclonal antibody (PC61) before tumor challenge did not enhance vaccine efficacy, and adding anti–TGF-β did not affect Treg numbers in lymph nodes or tumors or their function. Also, TGF-β neutralization had no effect on interleukin-17–producing T cells, which are induced by TGF-β and interleukin-6. Absence of type II NKT cells, which induce myeloid cells to produce TGF-β, was not sufficient to eliminate all sources of suppressive TGF-β. Finally, the synergistic protection induced by anti–TGF-β vaccine augmentation was mediated by CD8<sup>+</sup> T cells since anti-CD8 treatment completely abrogated the effect.</p><p><b>Conclusions:</b> These results suggest that TGF-β blockade may be useful for enhancing cancer vaccine efficacy. (Clin Cancer Res 2009;15(21):6560–9)</p></div>" @default.
- W4361949063 created "2023-04-05" @default.
- W4361949063 creator A5024024043 @default.
- W4361949063 creator A5039385026 @default.
- W4361949063 creator A5048688552 @default.
- W4361949063 creator A5056265030 @default.
- W4361949063 creator A5062001972 @default.
- W4361949063 creator A5081539344 @default.
- W4361949063 creator A5083493749 @default.
- W4361949063 creator A5086416923 @default.
- W4361949063 date "2023-03-31" @default.
- W4361949063 modified "2023-10-16" @default.
- W4361949063 title "Data from Synergistic Enhancement of CD8<sup>+</sup> T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody" @default.
- W4361949063 doi "https://doi.org/10.1158/1078-0432.c.6517897.v1" @default.
- W4361949063 hasPublicationYear "2023" @default.
- W4361949063 type Work @default.
- W4361949063 citedByCount "0" @default.
- W4361949063 crossrefType "posted-content" @default.
- W4361949063 hasAuthorship W4361949063A5024024043 @default.
- W4361949063 hasAuthorship W4361949063A5039385026 @default.
- W4361949063 hasAuthorship W4361949063A5048688552 @default.
- W4361949063 hasAuthorship W4361949063A5056265030 @default.
- W4361949063 hasAuthorship W4361949063A5062001972 @default.
- W4361949063 hasAuthorship W4361949063A5081539344 @default.
- W4361949063 hasAuthorship W4361949063A5083493749 @default.
- W4361949063 hasAuthorship W4361949063A5086416923 @default.
- W4361949063 hasBestOaLocation W43619490632 @default.
- W4361949063 hasConcept C153911025 @default.
- W4361949063 hasConcept C167672396 @default.
- W4361949063 hasConcept C185592680 @default.
- W4361949063 hasConcept C203014093 @default.
- W4361949063 hasConcept C2776090121 @default.
- W4361949063 hasConcept C2778690821 @default.
- W4361949063 hasConcept C2779727006 @default.
- W4361949063 hasConcept C502942594 @default.
- W4361949063 hasConcept C79484868 @default.
- W4361949063 hasConcept C86803240 @default.
- W4361949063 hasConcept C8891405 @default.
- W4361949063 hasConceptScore W4361949063C153911025 @default.
- W4361949063 hasConceptScore W4361949063C167672396 @default.
- W4361949063 hasConceptScore W4361949063C185592680 @default.
- W4361949063 hasConceptScore W4361949063C203014093 @default.
- W4361949063 hasConceptScore W4361949063C2776090121 @default.
- W4361949063 hasConceptScore W4361949063C2778690821 @default.
- W4361949063 hasConceptScore W4361949063C2779727006 @default.
- W4361949063 hasConceptScore W4361949063C502942594 @default.
- W4361949063 hasConceptScore W4361949063C79484868 @default.
- W4361949063 hasConceptScore W4361949063C86803240 @default.
- W4361949063 hasConceptScore W4361949063C8891405 @default.
- W4361949063 hasLocation W43619490631 @default.
- W4361949063 hasLocation W43619490632 @default.
- W4361949063 hasOpenAccess W4361949063 @default.
- W4361949063 hasPrimaryLocation W43619490631 @default.
- W4361949063 hasRelatedWork W1557803273 @default.
- W4361949063 hasRelatedWork W2085226443 @default.
- W4361949063 hasRelatedWork W2138864047 @default.
- W4361949063 hasRelatedWork W2366649094 @default.
- W4361949063 hasRelatedWork W2384344522 @default.
- W4361949063 hasRelatedWork W2767749856 @default.
- W4361949063 hasRelatedWork W2995822774 @default.
- W4361949063 hasRelatedWork W3214820661 @default.
- W4361949063 hasRelatedWork W4327734445 @default.
- W4361949063 hasRelatedWork W4366173980 @default.
- W4361949063 isParatext "false" @default.
- W4361949063 isRetracted "false" @default.
- W4361949063 workType "article" @default.